Aurobindo Pharma Limited — Q3 FY26
Aurobindo Pharma reported a strong quarter with PAT of INR 910 crore, supported by improving Pen G yields and a favorable government MIP policy on key antibiotics.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
FY26 EBITDA margin target of 20-21%
Management reiterated confidence in achieving internal margin target of 20-21% for FY26, driven by operational leverage and cost efficiency.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
China OSG facility EBITDA breakeven by Q3-Q4 FY26
The OSG facility in China is on track to deliver EBITDA breakeven by Q3-Q4 FY26, with European approval for 10 products and 3 local approvals.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1